Ariad Pharmaceuticals and Merck have submitted a marketing authorization application (MAA) for ridaforolimus with the EMA. Merck is planning global submissions for ridaforolimus in Europe, the U.S., Canada, Asia-Pacific and Latin America and other key markets. Acceptance of the MAA will trigger a $25 million milestone payment to Ariad. The company will also receive a $25 million milestone payment upon approval in the U.S., while approval to sell ridaforolimus in the EU will secure a $10 million ...